Ratings by UBS (Alice Nettleton)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/12/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Buy (Buy) |
|
Details | ||
| 10/12/2026 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Neutral (N/A) |
22.38 (20.76) |
-7.24% | Details | |
| 10/12/2026 | BioAge Labs Inc | BIOA | New Coverage | Neutral (N/A) |
6.21 (5.42) |
-12.72% | Details | |
| 10/12/2026 | Shattuck Labs | STTK | New Coverage | Buy (N/A) |
5.66 (5.33) |
-5.83% | Details | |
| 10/12/2026 | Odyssey Therapeutics | ODTX | New Coverage | Buy (N/A) |
18.12 (16.60) |
-8.39% | Details | |
| 10/12/2026 | Kardigan Inc | KARD | New Coverage | Buy (N/A) |
14.20 (13.52) |
-4.79% | Details | |
| 10/12/2026 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
40.80 (36.89) |
-9.58% | Details | |
| 10/12/2026 | Ocular Therapeutix | OCUL | New Coverage | Buy (N/A) |
7.51 (7.20) |
-4.13% | Details | |
| 10/12/2026 | Evommune Inc | EVMN | New Coverage | Neutral (N/A) |
6.41 (5.77) |
-9.98% | Details | |
| 10/12/2026 | AbCellera Biologics | ABCL | New Coverage | Buy (N/A) |
12.02 (12.37) |
2.91% | Details | |
| 10/12/2026 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
139.91 (136.28) |
-2.59% | Details | |
| 10/12/2026 | Tectonic Therapeutics Inc. | TECX | New Coverage | Neutral (N/A) |
22.75 (20.96) |
-7.87% | Details | |
| 10/12/2026 | Spyre | SYRE | New Coverage | Buy (N/A) |
79.90 (78.63) |
-1.59% | Details |
